PepVault News

A semaglutide implant matched weekly Wegovy shots in its first human trial, with no drug side effects

Phase 1 trial in 20 people, 4 weeks, low dose; company top-line data, not peer reviewed.

Vivani Medical's NPM-139, a small implant built to release semaglutide for months, gave the same weight loss as Wegovy's starting dose over 4 weeks. None of the 10 people on it had a side effect tied to the drug.

What happened

Vivani Medical reported top-line results from SLIM-1 on November 12, 2026. It is the first trial of NPM-139, a semaglutide implant placed under the skin, in people.

The phase 1 trial ran at a single center in Australia. Ten overweight or obese adults, otherwise healthy, got a low-dose NPM-139 implant. Another ten got Wegovy at its starting dose, 0.25 mg a week, as the comparison group. Both groups were followed for four weeks.

The numbers

Weight loss was the same in both groups: 0.79% on the implant and 0.82% on Wegovy. Over four weeks at a low dose, small numbers are expected; the trial was built to check safety and how the drug is released, not to show maximum weight loss.

None of the 10 people on the implant had a side effect the investigators tied to the treatment. On Wegovy, 5 of 10 did, all of them gut side effects, which is in line with what GLP-1 shots usually cause. There were no serious side effects in either group, and putting in and taking out the implants went without complications.

Why the release matters

Drug levels on the implant rose slowly and peaked at about 16 days, against about 2.4 days after a Wegovy shot. The company says there were no sudden jumps in drug level. Fast rises in GLP-1 levels are linked to nausea and the other gut effects that make many people stop their shots.

NPM-139 is being designed to be placed once or twice a year, and to be removed quickly if someone needs to stop, for example before a pregnancy.

What comes next

Vivani plans a phase 2 trial that will test different doses for keeping weight off, expected to start in 2027. Novo Nordisk, which makes Wegovy and Ozempic, is evaluating the implant technology under a non-exclusive agreement announced in July 2026.

These are the company's own top-line results from a small, short trial. They have not been published in a journal, and the implant is not approved anywhere.

The numbers

  • Phase 1 SLIM-1: 20 adults, 10 on the NPM-139 implant and 10 on Wegovy 0.25 mg weekly, for 4 weeks
  • Weight loss: 0.79% on the implant vs 0.82% on Wegovy
  • Side effects tied to treatment: 0 of 10 on the implant vs 5 of 10 on Wegovy (all gut)
  • Peak drug level at about 16 days on the implant vs about 2.4 days on Wegovy
  • Phase 2 expected to start in 2027

The original: Vivani Medical press release (GlobeNewswire)

PepVault for iPhone

Track it in the app.

Log your doses, vials and injection sites, with every peptide’s studied range a tap away.

Download on the App Store